Probiotics administration following sleeve gastrectomy surgery: a randomized double-blind trial

Background: Probiotics are commonly used after bariatric surgery; however, uncertainty remains regarding their efficacy. Our aim was to compare the effect of probiotics vs placebo on hepatic, inflammatory and clinical outcomes following laparoscopic sleeve gastrectomy (LSG). Methods: This randomized...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International Journal of Obesity 2018-02, Vol.42 (2), p.147-155
Hauptverfasser: Sherf-Dagan, S, Zelber-Sagi, S, Zilberman-Schapira, G, Webb, M, Buch, A, Keidar, A, Raziel, A, Sakran, N, Goitein, D, Goldenberg, N, Mahdi, J A, Pevsner-Fischer, M, Zmora, N, Dori-Bachash, M, Segal, E, Elinav, E, Shibolet, O
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Probiotics are commonly used after bariatric surgery; however, uncertainty remains regarding their efficacy. Our aim was to compare the effect of probiotics vs placebo on hepatic, inflammatory and clinical outcomes following laparoscopic sleeve gastrectomy (LSG). Methods: This randomized, double-blind, placebo-controlled, trial of 6-month treatment with probiotics (Bio-25; Supherb) vs placebo and 6 months of additional follow-up was conducted among 100 morbidly obese nonalcoholic fatty liver disease (NAFLD) patients who underwent LSG surgery. The primary outcome was a reduction in liver fat content, measured by abdominal ultrasound, and secondary outcomes were improvement of fibrosis, measured by shear-wave elastography, metabolic and inflammatory parameters, anthropometrics and quality of life (QOL). Fecal samples were collected and analyzed for microbial composition. Results: One hundred patients (60% women, mean age of 41.9±9.8 years and body mass index of 42.3±4.7 kg m −2 ) were randomized, 80% attended the 6-month visit and 77% completed the 12-month follow-up. Fat content and NAFLD remission rate were similarly reduced in the probiotics and placebo groups at 6 months postsurgery (−0.9±0.5 vs −0.7±0.4 score; P =0.059 and 52.5 vs 40%; P =0.262, respectively) and at 12 months postsurgery. Fibrosis, liver-enzymes, C-reactive protein (CRP), leptin and cytokeratin-18 levels were significantly reduced and QOL significantly improved within groups ( P ⩽0.014 for all), but not between groups ( P ⩾0.173 for all) at 6 and 12 months postsurgery. Within-sample microbiota diversity (alpha-diversity) increased at 6-month postsurgery compared with baseline in both study arms ( P ⩽0.008) and decreased again at 12 months postsurgery compared with 6 months postsurgery ( P ⩽0.004) but did not reach baseline values. Conclusions: Probiotics administration does not improve hepatic, inflammatory and clinical outcomes 6- and 12 months post-LSG.
ISSN:0307-0565
1476-5497
DOI:10.1038/ijo.2017.210